click below
click below
Normal Size Small Size show me how
Pharm 5018 ETSU NP
cH 12 Pharmacoeconomics
Question | Answer |
---|---|
Pharmacoeconomic Studies | Designed to only look at economic impact of therapy Need to think of clinical impact Components of well-designed studies |
Pharmacoeconomic Studies | Point of view/Types of costs/Direct/Indirect/Intangible |
Cost of Illness Analysis | The costs of a specific disease in a given population/ Costs of resources needed to treat illness/Costs of nonmedical resources/Loss of productivity |
Cost-Minimization Analysis | Compares the costs of two or more treatment alternatives that are considered equal in efficacy Compares cost of drugs within a class |
Cost-Minimization Analysis | Compares the costs of two or more treatment alternatives that are considered equal in efficacy Compares cost of drugs within a class |
Cost-Effectiveness Analysis | Two or more treatments/programs that are not necessarily therapeutically equivalent Measures effectiveness in therapeutic outcomes vs. dollars saved |
Cost-Benefit Analysis | The costs of a specific treatment or intervention are calculated and then compared with the dollar value of the benefit received. Compare and determine greatest benefit for the dollar spent. |
Cost-Benefit Analysis | Cost-benefit ratio Difference in two therapies |
Cost-Utility Analysis | Costs of the treatment choice are in dollars and the outcomes are expressed in terms of pt/pref or quality-adjusted life years/ Used when quality of life is a factor |
Generic Drugs | Generic drugs may or may not be less expensive. Pharmacy coverage may determine whether a generic is used. |
Generic Drugs | Tiered benefit Lower co-pay for generic drugs Retail prescription drug programs |
Generic Substitution | 69% of prescriptions are filled with generic drugs. Prescriber influenced by Innovator company |
Generic Substitution | Payer Patient Innovator companies support for health care |
Bioequivalence | The U.S. Food and Drug Administration (FDA) regulates and sets standards for bioequivalence. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations |
Bioequivalence | Available online/Search by active ingredient/Search by proprietary name/Updated daily |
Pharmacoeconomics in Practice | Prescribing generic vs. brand-name drugs Pharmacist may substitute a less expensive drug that is therapeutic equivalent. “Dispense as Written” |
Pharmacoeconomics in Practice | Patients may switch due to costs and prescription benefit. Retail drug programs |
Pharmacoeconomics in Practice | Walmart, Target, Kroger, Sam’s Club $4 for a 30-day supply of common generic drugs |
Medicare Part D | Covers 75% of drug costs once the patient pays a deductable of $250/year Prescription costs between $250 and $2,250 costs the patient 25% of the price of the medication |
Medicare Part D | Patient pays 100% between $2,250 and $5,100 Prescriptions covered 100% after $5,100/year |
Changes to Part D Due to Reform | 2010 enrollees in the “doughnut hole” will get $250 rebate. 2011 enrollees will get a 50% discount on brand-name drugs during the gap. |
Changes to Part D Due to Reform | Drug costs in the gap will be gradually reduced from 100% to 25% by 2020. 50% for brand-name drugs/25% for generic drugs |
Conclusion | Pharmacoeconomics influence every prescription. Understand your generic equivalents. Consult with pharmacist. |
Conclusion | Use Orange Book. Collaborate with the patient regarding costs. |
Conclusion | Generic vs. brand-name drugs Ask about their prescription coverage. |